tiprankstipranks
Advertisement
Advertisement

ABBV Stock Latest News

2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
Market News2 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now for August Payouts
12h ago
ABT
SPX
AbbVie price target raised to $280 from $260 at RBC Capital
PremiumThe Fly
AbbVie price target raised to $280 from $260 at RBC Capital
23h ago
ABBV
AbbVie price target raised to $276 from $234 at BofA
PremiumThe Fly
AbbVie price target raised to $276 from $234 at BofA
1d ago
ABBV
AbbVie price target raised to $295 from $260 at Wells Fargo
PremiumThe Fly
AbbVie price target raised to $295 from $260 at Wells Fargo
1d ago
ABBV
AbbVie price target raised to $280 from $260 at JPMorgan
PremiumThe Fly
AbbVie price target raised to $280 from $260 at JPMorgan
2d ago
ABBV
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
PremiumTipRanks NewswireThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush
2d ago
LLY
ABBV
AbbVie price target raised to $261 from $249 at Guggenheim
Premium
The Fly
AbbVie price target raised to $261 from $249 at Guggenheim
2d ago
ABBV
AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
Premium
Company Announcements
AbbVie’s ABBV‑277 Trial Completion: What Early Safety Data Could Mean for Investors
3d ago
ABBV
Closing Bell Movers: Crinetics doubles on Vertex buyout
PremiumThe Fly
Closing Bell Movers: Crinetics doubles on Vertex buyout
5d ago
RTO
STX
AbbVie says Q2 EPS to include unfavorable impact of 17c
PremiumThe Fly
AbbVie says Q2 EPS to include unfavorable impact of 17c
5d ago
ABBV
AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77
PremiumThe Fly
AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77
5d ago
ABBV
AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28
PremiumThe Fly
AbbVie cuts FY26 adjusted EPS view to $13.91-$14.11 from $14.08-$14.28
5d ago
ABBV
Genmab says EC grants marketing authorization for Tepkinly combo
PremiumThe FlyGenmab says EC grants marketing authorization for Tepkinly combo
5d ago
ABBV
GMAB
AbbVie says Tepkinly combo approved by EC for lymphoma treatment
Premium
The Fly
AbbVie says Tepkinly combo approved by EC for lymphoma treatment
5d ago
ABBV
AbbVie price target raised to $300 from $275 at HSBC
Premium
The Fly
AbbVie price target raised to $300 from $275 at HSBC
5d ago
ABBV
AbbVie price target raised to $265 from $240 at Cantor Fitzgerald
PremiumThe Fly
AbbVie price target raised to $265 from $240 at Cantor Fitzgerald
5d ago
ABBV
AbbVie’s CoolSculpting Elite Study Update Strengthens Aesthetics Outlook
PremiumCompany Announcements
AbbVie’s CoolSculpting Elite Study Update Strengthens Aesthetics Outlook
9d ago
ABBV
Trial Termination Shifts Outlook for AbbVie’s Epcoritamab in Frontline Lymphoma
PremiumCompany Announcements
Trial Termination Shifts Outlook for AbbVie’s Epcoritamab in Frontline Lymphoma
9d ago
ABBV
House committee opens probe into Merck, AbbVie China drug trials, Reuters says
PremiumThe Fly
House committee opens probe into Merck, AbbVie China drug trials, Reuters says
11d ago
MRK
ABBV
Genmab announces topline results from EPCORE DLBCL-4 trial
PremiumThe FlyGenmab announces topline results from EPCORE DLBCL-4 trial
12d ago
ABBV
GMAB
AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial
Premium
The Fly
AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial
12d ago
ABBV
GMAB
AbbVie’s FAST Study Wraps Up: Real-World Checkup on Ubrogepant’s Migraine Performance
Premium
Company Announcements
AbbVie’s FAST Study Wraps Up: Real-World Checkup on Ubrogepant’s Migraine Performance
12d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >